Atherosclerosis
Volume 205, Issue 1 , Pages 325-330 , July 2009

Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women

  • Stefania Lamon-Fava

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 617 556 3105; fax: +1 617 556 3103.
    • ,
  • David M. Herrington

      Affiliations

    • Department of Internal Medicine – Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC, United States
    • ,
  • David M. Reboussin

      Affiliations

    • Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, United States
    • ,
  • Michelle Sherman

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, United States
    • ,
  • Katalin Horvath

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, United States
    • ,
  • Ernst J. Schaefer

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, United States
    • ,
  • Bela F. Asztalos

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, United States

Received 24 June 2008 ,Revised 17 October 2008 ,Accepted 9 December 2008.

References 

  1. Hulley SB, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  2. Herrington DM, Reboussin DM, Brosnihan B, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522–529
  3. Clarke S, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischemic heart disease: the Papworth HRT atherosclerosis study. Brit J Obstet Gynaec. 2002;109:1056–1062
  4. Angerer P, Stork S, Kothny W, et al. Effects of oral postmenopausal hormone replacement on progression of atherosclerosis. A randomized, controlled trial. Arterioscl Throm Vas. 2001;21:262–268
  5. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  6. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  7. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of epidemiologic evidence. Prev Med. 1991;20:47–63
  8. Clarkson T, Anthony M, Wagner J. A comparison of tibolone and conjugated equine estrogens effects on coronary atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocr Metab. 2001;86:5396–5404
  9. Rossouw J, Prentice R, Manson JA, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477
  10. Smith N, Keckbert S, Lemaitre R, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thormbosis. JAMA. 2004;292:1581–1587
  11. Seli E, Guzeloglu-Kayisli O, Cakman H, et al. Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating Fas and Fas ligand expression. J Clin Endocr Metab. 2006;91:4995–5001
  12. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716
  13. Mendelsohn M, Karas R. Molecular and cellular basis of cardiovascular gender differences. Science. 2007;308:1583–1587
  14. McNamara JR, Shah PK, Nakajiam K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154:229–236
  15. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscl Throm Vas. 2005;25:2185–2191
  16. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscl Throm Vas. 2004;24:2181–2187
  17. Herrington DM, Reboussin DM, Klein K, et al. Estrogen Replacement and Atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin Trials. 2000;21:257–285
  18. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma lipoprotein fractions. Clin Chim Acta. 1987;166:1–8
  19. Burstein M, Samaille J. Sur un dosage rapide du cholesterol lie aux alpha- et aux beta-lipoproteines du serum. Clin Chim Acta. 1960;5:609
  20. Contois J, McNamara J, Lammi-Keefe C, et al. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem. 1996;42:507–514
  21. McNamara JR, Shah PK, Nakajima K, et al. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin Chem. 1998;44:1224–1232
  22. Asztalos BF, Sloop CH, Wong L, et al. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta. 1993;1169:291–300
  23. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164:1427–1436
  24. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453–1460
  25. Athyros V, Mikhailidis D, Papageorgiou A, et al. Effect of atorvastatin on high density lipoprotein-cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004;20:627–637
  26. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–1591
  27. Lamon-Fava S, Postfai B, Asztalos BF, et al. Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high-density lipoproteins. Metabolism. 2004;52:1330–1336
  28. Sanada M, Nakagawa H, Kodama I, et al. The effect of hormone replacement therapy on metabolism of lipoprotein remants in postmenopausal women. Maturitas. 2000;34:75–82
  29. Westerveld H, Kock LAW, Rijn HJM, et al. 17 Beta-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocr Metab. 1995;80:249–253
  30. Ossewaarde M, Dallinga-Thie G, Bots M, et al. Treatment with hormonal replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. Eur J Clin Invest. 2003;33:376–382
  31. Bittner V, Tripputi M, Hsia J, et al. Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women’s Angiographic Vitamin & Estrogen trial. Am Heart J. 2004;148:293–299
  32. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New Engl J Med. 1991;325:1196–1204
  33. Bruning JC, Lingohr P, Gillette J, et al. Estrogen receptor alpha and Sp1 interact in the induction of the low density lipoprotein-receptor. J Steroid Biochem. 2003;86:113–121
  34. Lamon-Fava S, Postfai B, Diffenderfer M, et al. Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women.. Arterioscl Throm Vas. 2006;26:385–391
  35. Landschulz KT, Pathak RK, Rigotti AKM, et al. Regulation of scavenger receptor, class B, type 1, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. Eur J Clin Invest. 1996;98:984–995
  36. Rigotti A, Trigatti BL, Penman M, et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA. 1997;94:12610–12615
  37. Fukushima H, Kugiyama K, Sugiyama S, et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol. 2001;88:1370–1373
  38. Lamon-Fava S, Herrington DM, Reboussin DM, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscl Throm Vas. 2008;28:575–579
  39. The Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  40. Miida T, Nakamura Y, Inano K, et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem. 1996;42:1992–1995
  41. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.. Arterioscl Throm Vas. 2003;23:847–852
  42. Asztalos BF, Schaefer EJ. The effects of statins on high-density lipoproteins. Curr Atherosclerosis Rep. 2006;8:41–49
  43. Tilly-Kiesi M, Kahri J, Pyorala T, et al. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Atherosclerosis. 1997;129:249–259
  44. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18:427–434
  45. Lamon-Fava S, Micherone D. Regulation of apo A-I gene expression: mechanism of action of estrogen and genistein. J Lipid Res. 2004;45:106–112
  46. Ouyang P, Tardif JC, Herrington DM, et al. Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis. 2006;189:375–386

PII: S0021-9150(08)00901-5

doi: 10.1016/j.atherosclerosis.2008.12.020

Atherosclerosis
Volume 205, Issue 1 , Pages 325-330 , July 2009

Article Tools

* Image Usage & Resolution